Global support for a quality solution
We lead innovation in peptide API’s to the benefit of millions of patients
Contact usResults 2022 – scaling up for accelerated growth
Learn moreAhead on green peptide chemistry
Together we improve process performance while reducing the environmental footprint
Learn moreMarket leader in peptide API manufacturing and services
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API).
Ad hoc announcements pursuant to Art. 53 LR
Transformational progress taking shape, profitability impacted by rapid expansion – appointment of Marc Augustin as new CFO
15 Aug 2023 - Baar, 15 August 2023 – PolyPeptide today announced its results for H1 2023, updated guidance for 2023 and the appointment of its new CFO: Reported results […]
Read moreAd hoc announcements pursuant to Art. 53 LR
PolyPeptide delivers revenue of around EUR 132 million for H1 – expects net loss for H1 and full year 2023
13 Jul 2023 - Baar, July 13th, 2023 – PolyPeptide Group AG (SIX: PPGN) achieves H1 2023 revenue of around EUR 132 million driven by strong momentum in its peptide […]
Read more